DK1126867T3 - Sammensætning til forebyggelse og/eller behandling af åreforkalkning - Google Patents

Sammensætning til forebyggelse og/eller behandling af åreforkalkning

Info

Publication number
DK1126867T3
DK1126867T3 DK99970026T DK99970026T DK1126867T3 DK 1126867 T3 DK1126867 T3 DK 1126867T3 DK 99970026 T DK99970026 T DK 99970026T DK 99970026 T DK99970026 T DK 99970026T DK 1126867 T3 DK1126867 T3 DK 1126867T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
prevention
treatment
composition
low density
Prior art date
Application number
DK99970026T
Other languages
Danish (da)
English (en)
Inventor
Yehuda Shoenfeld
Dror Harats
Jacob George
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Application granted granted Critical
Publication of DK1126867T3 publication Critical patent/DK1126867T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
DK99970026T 1998-10-04 1999-09-30 Sammensætning til forebyggelse og/eller behandling af åreforkalkning DK1126867T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12644798A IL126447A (en) 1998-10-04 1998-10-04 An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
PCT/IL1999/000519 WO2000020019A2 (en) 1998-10-04 1999-09-30 A composition for the prevention and/or treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
DK1126867T3 true DK1126867T3 (da) 2003-09-08

Family

ID=11072009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99970026T DK1126867T3 (da) 1998-10-04 1999-09-30 Sammensætning til forebyggelse og/eller behandling af åreforkalkning

Country Status (16)

Country Link
US (2) US20030114367A1 (de)
EP (1) EP1126867B1 (de)
JP (1) JP4834219B2 (de)
KR (1) KR100680707B1 (de)
CN (2) CN1176716C (de)
AT (1) ATE240115T1 (de)
AU (1) AU760582B2 (de)
BR (1) BR9914631A (de)
CA (1) CA2345445C (de)
DE (1) DE69907945T2 (de)
DK (1) DK1126867T3 (de)
ES (1) ES2198163T3 (de)
HU (1) HUP0104410A3 (de)
IL (1) IL126447A (de)
PT (1) PT1126867E (de)
WO (1) WO2000020019A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
JP4789311B2 (ja) * 1999-07-16 2011-10-12 エンゾー セラピューティクス， インコーポレイテッド 新規の選択的免疫ダウンレギュレーション（ｓｉｄｒ）媒介性移植プロセス、被験体における疾患を予防または処置するためのプロセス、およびｓｉｄｒを確立するために有用である、馴化またはプログラミングされた細胞、組織または器官を含む組成物
JP2004501061A (ja) * 1999-12-15 2004-01-15 ペプトル・リミテツド 熱ショックタンパク質６０のフラグメントおよびアンタゴニスト
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
FR2816060A1 (fr) * 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
EP1355664A4 (de) * 2001-01-04 2005-10-26 Vascular Biogenics Ltd "verfahren, bei denen plaque?assoziierte moleküle verwendet werden sowie zusammensetzungen, die diese enthalten; für die vorbeugung und behandlung von atheriosklerose"
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
ATE510553T1 (de) * 2002-05-17 2011-06-15 Univ Texas Beta-2-glycoprotein 1 als angiogenesehemmer
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
EP1676602A1 (de) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Kontinuierlicheverabreichung von Epitope aus dem atherosklerotischem Belag zur Behandlung von Atheriosklerose
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
WO2007054587A1 (en) * 2005-11-14 2007-05-18 Nestec S.A. Oral tolerance promotion with glycated proteins
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
EP2281007B1 (de) * 2008-04-10 2014-07-09 Thrombosis Research Institute Anti-atheroma impstoff
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP2328911A4 (de) 2008-09-22 2012-03-14 Cedars Sinai Medical Center Kurzes menschliches md-2 als negativer regulator der toll-like-rezeptor-4-signalisierung
CN103185801B (zh) * 2011-12-30 2015-04-15 深圳市亚辉龙生物科技有限公司 一种检测抗β2糖蛋白I抗体的试剂装置及其方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948262A (en) * 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3699963A (en) * 1969-10-31 1972-10-24 Alza Corp Therapeutic adhesive patch
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3944064A (en) * 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
JPS61130238A (ja) * 1984-11-30 1986-06-18 Res Dev Corp Of Japan 動脈硬化巣認識モノクロナル抗体および反応試薬
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US6019970A (en) * 1985-07-31 2000-02-01 Ghent William R. Treatment of iodine deficiency diseases
DE3750369T2 (de) * 1986-03-21 1995-05-24 Eurasiam Lab Arzneimittelzusammensetzungen.
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE3775830D1 (de) * 1986-06-13 1992-02-20 Alza Corp Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit.
CN1093255A (zh) * 1986-06-17 1994-10-12 恩特雷麦德有限公司 抗甾醇疫苗
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4917895A (en) * 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4837027A (en) * 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
DK0482089T3 (da) * 1989-07-14 1998-05-25 Autoimmune Inc Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
WO1991006006A1 (en) * 1989-10-19 1991-05-02 Yamasa Shoyu Kabushiki Kaisha Carrier for binding antiphospholipid antibody, immunoassay using the same, and kit therefor
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US6077509A (en) * 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
JPH04506415A (ja) * 1990-04-06 1992-11-05 ヤマサ醤油株式会社 リン脂質およびその抗体の測定方法
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
ATE127925T1 (de) * 1990-04-06 1995-09-15 Yamasa Shoyu Kk Verfahren zur bestimmung von antiphospholipid antikörpern.
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
DK0590060T3 (da) * 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
AU666352B2 (en) * 1992-02-05 1996-02-08 Takao Koike Solid-phase reagent and assay method for measuring antibodies specific to antiphospholipid syndrome
US6130059A (en) * 1992-03-02 2000-10-10 Covacci; Antonello Helicobacter pylori proteins useful for vaccines and diagnostics
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5409710A (en) * 1993-04-20 1995-04-25 Endocon, Inc. Foam cell drug delivery
WO1995009363A1 (en) * 1993-09-29 1995-04-06 Yamasa Corporation Method of assaying oxidized lipoprotein and application thereof
US5844409A (en) * 1993-10-01 1998-12-01 Siemens Aktiengesellschaft Method and system for measuring an electric current with two light signals propagating in opposite directions, using the Faraday effect
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
CA2176007A1 (en) * 1993-11-16 1995-05-26 Eiji Matsuura Method of assaying antiphospholipid antibody and kit therefor
WO1995025744A1 (en) * 1994-03-21 1995-09-28 Rijksuniversiteit Utrecht Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
DE4413938A1 (de) * 1994-04-21 1995-11-02 Gerhild Dr Wildner Peptide als Therapeutikum für Autoimmunerkrankungen
US6156500A (en) * 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
IL122502A0 (en) * 1995-06-07 1998-06-15 Autoimmune Inc Medicaments for inducing oral tolerance in skin diseases presenting with t-cell mediated inflammation
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
TW460753B (en) * 1995-07-20 2001-10-21 Shinetsu Chemical Co Chemically amplified positive resist material
FR2742989B1 (fr) * 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6019975A (en) * 1997-11-13 2000-02-01 Elizabeth Arden Co., Division Of Conopco, Inc. Antisebum and antioxidant compositions containing a low molecular weight fraction of gugulipid
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
US7067109B1 (en) * 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20050148499A1 (en) * 1998-10-04 2005-07-07 Dror Harats Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of atherosclerosis
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
EP1355664A4 (de) * 2001-01-04 2005-10-26 Vascular Biogenics Ltd "verfahren, bei denen plaque?assoziierte moleküle verwendet werden sowie zusammensetzungen, die diese enthalten; für die vorbeugung und behandlung von atheriosklerose"
EP1368354A1 (de) * 2001-03-07 2003-12-10 Pfizer Products Inc. Modulatoren der aktivität von chemokin-rezeptoren
US20030100036A1 (en) * 2001-11-08 2003-05-29 Aristo Vojdani Saliva immunoassay for detection of antibodies for cardiovascular disease

Also Published As

Publication number Publication date
DE69907945D1 (de) 2003-06-18
WO2000020019A3 (en) 2000-06-09
JP4834219B2 (ja) 2011-12-14
AU760582B2 (en) 2003-05-15
KR100680707B1 (ko) 2007-02-08
US20030114367A1 (en) 2003-06-19
CN1332636A (zh) 2002-01-23
HUP0104410A3 (en) 2004-07-28
EP1126867B1 (de) 2003-05-14
CN100430090C (zh) 2008-11-05
IL126447A0 (en) 1999-08-17
US20020025321A1 (en) 2002-02-28
WO2000020019A2 (en) 2000-04-13
CA2345445C (en) 2010-08-24
CA2345445A1 (en) 2000-04-13
BR9914631A (pt) 2001-07-03
JP2002526416A (ja) 2002-08-20
HK1043743A1 (en) 2002-09-27
ATE240115T1 (de) 2003-05-15
HUP0104410A2 (hu) 2002-03-28
CN1616085A (zh) 2005-05-18
PT1126867E (pt) 2003-09-30
ES2198163T3 (es) 2004-01-16
HK1076600A1 (zh) 2006-01-20
KR20010083886A (ko) 2001-09-03
IL126447A (en) 2004-09-27
AU5996699A (en) 2000-04-26
CN1176716C (zh) 2004-11-24
DE69907945T2 (de) 2004-03-11
EP1126867A2 (de) 2001-08-29

Similar Documents

Publication Publication Date Title
DK1126867T3 (da) Sammensætning til forebyggelse og/eller behandling af åreforkalkning
ATE297200T1 (de) Facettenreiches verfahren zur unterdrückung der vermehrung latenter viren in menschen und tieren
TR200002299T2 (tr) Epotilon kompozisyonları.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
SI1037607T1 (en) Novel suppository form comprising an acid-labile active compound
ITRM920476A1 (it) Formulazioni galeniche contenenti ciclosporina.
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
NL300136I1 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
DK0977562T3 (da) Fremgangsmåder og sammensætninger til indgivelse af taxaner
BR9609537A (pt) Composições farmacêuticas
ATE221770T1 (de) Topische mittel
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
BG103677A (en) Solid mixtures based on sulphonylcarbamides and adjuvants
FI913556A0 (fi) Nya piperidyletrar och -tioetrar som inhibitorer av kolesterolbiosyntes.
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
DK1235579T3 (da) Farmaceutiske præparater med indhold af trimegeston
DK1061938T3 (da) Orale sammensætninger med cytotoksiske proteiner i lav dosis
FR2711370B1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2711369B1 (fr) Nouveaux taxoïdes, leur préparation et les compositions qui les contiennent.
GR1002385B (el) Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.
MA23574A1 (fr) Nouveaux derives alcanes 1,1-bis (heteroazolyl) et leur utilisation comme agents neuro-inhibiteurs
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
FR2710642B1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
Lugscheider et al. Active Brazing--A Joining Technology for Oxide and Nonoxide Engineering Ceramics
IL193593A0 (en) A polypeptide containing an immunogenic portion of a m. tuberculosis antigen, and pharmaceutical compositions containing the same